Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -211.61M | -202.93M | -187.08M | -165.76M | -137.07M |
| Total Depreciation and Amortization | 321.00K | 327.00K | 330.00K | 327.00K | 322.00K |
| Total Amortization of Deferred Charges | 1.39M | 1.23M | 1.19M | 860.00K | 538.00K |
| Total Other Non-Cash Items | 20.75M | 21.14M | 19.64M | 17.95M | 15.57M |
| Change in Net Operating Assets | 22.37M | 19.85M | 10.64M | 11.28M | 4.01M |
| Cash from Operations | -166.78M | -160.38M | -155.28M | -135.34M | -116.63M |
| Capital Expenditure | -20.00K | -20.00K | -19.00K | -139.00K | -151.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -20.00K | -20.00K | -19.00K | -139.00K | -151.00K |
| Total Debt Issued | 0.00 | 30.00M | 98.60M | 98.60M | 98.60M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25.22M | 25.26M | 25.20M | 283.00K | 233.00K |
| Repurchase of Common Stock | -27.00K | -27.00K | -27.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -739.00K | -739.00K | -3.39M | -2.65M | -2.65M |
| Cash from Financing | 24.45M | 54.50M | 120.39M | 96.24M | 96.19M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -142.35M | -105.91M | -34.91M | -39.24M | -20.60M |